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The human EVI1 gene spans approximately 65 kb of 
genomic DNA. 14 of its 16 exons are coding (Fig. 1A). 
Transcription can initiate from alternative exons 1a, b,  
1c, 1d, or 3L (Fig. 1B), and several alternative splice 
variants of the EVI1 mRNA have been described 
(Delta324, -Rp9, Delta105; Fig. 1A). 
The human MDS1 gene consists of 4 exons spread over 
a genomic region of more than 500 kb. MDS1 exon 4 is 
located less than 2 kb upstream of EVI1 exon1a. The 
MDS1-EVI1 mRNA presumably results from splicing 
of the second exon of MDS1 to the second exon of 
EVI1 (Fig. 1B). 
Transcription 
Telomere to centromere. 
 
 
Figure 1. Genomic locus of the human EVI1 gene and EVI1 mRNA variants. Asterisk, translation initiation codon; diamond, translation 
stop codon. (This figure was reprinted from Gene 396, R. Wieser, 'The oncogene and developmental regulator EVI1: Expression, 
biochemical properties, and biological functions', pages 346-357, Copyright Elsevier (2007), with permission from Elsevier. Gene 
homepage: http://www.sciencedirect.com/science/journal/03781119). 
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Figure 2. A) EVI1 and B) MDS1/EVI1 protein domains and EVI1 interacting proteins. Black boxes, zinc finger motifs; RD, repression 
domain, with binding motifs for the transcriptional corepressor CtBP depicted as black bars; ac, acidic region; PR, PR domain. This 
figure was reprinted from Gene 396, R. Wieser, 'The oncogene and developmental regulator EVI1: Expression, biochemical properties, 




Exon 3 of the human EVI1 gene contains two closely 
spaced ATG codons, either of which may serve as the 
translation initiation site. Depending on which ATG is 
used, proteins of 1051 or 1041 amino acids will be 
formed. EVI1 contains two domains of seven and three 
zinc finger motifs, respectively, a repression domain 
between the two sets of zinc fingers, and an acidic 
domain of unknown function at its C-terminus. It is a 
145 kDa protein that is capable of binding to DNA in a 
sequence specific manner, and that interacts with 
transcriptional coactivators (P/CAF, CBP) and 
corepressors (CtBP, HDAC) as well as other sequence 
specific transcription factors (GATA1, Smad3). 
Predicted translation of MDS1-EVI1 adds 188 amino 
acids to the N-terminus of EVI1. 63 of these additional 
amino acids are derived from the untranslated second 
exon and the untranslated part of the third exon of 
EVI1, and the remaining 125 from the MDS1 gene. 
MDS1-EVI1 contains a PR domain, which is about 
40% homologous to the N-terminus of the 
retinoblastoma-binding protein, RIZ, and the PRDI-
BF1 transcription factor. Some biological functions of 
MDS1/EVI1 are different from, or even antagonistic to, 
those of EVI1. 
Expression 
In human tissues/organs, the EVI1 mRNA is expressed 
abundantly in kidney, lung, pancreas, stomach, ovaries, 
uterus, and prostate, to a lesser extent in the small 
intestine, colon, thymus, spleen, heart, brain, testis, and 
placenta, and at very low levels in skeletal muscle and 
bone marrow. The pattern of expression of MDS1-
EVI1 is very similar to that of EVI1. 
In the adult mouse, the Evi1 mRNA is expressed, at  
varying levels, in the kidney, lung, stomach, ovary, 
uterus, intestine, thymus, spleen, heart, brain, and liver. 
In the mouse embryo, Evi1 mRNA levels are high in 
the urinary system and Mullerian ducts, the lung, the
heart, and the emerging limb buds. 
Similar Evi1 expression patterns were also observed in 
Xenopus, chicken, and zebrafish. 
Localisation 
Nuclear; in part in speckles. 
Function 
Because of the spatially and temporally restricted 
expression of EVI1, it has been suggested that this gene 
plays an important role in development and could be 
involved in organogenesis, cell migration, cell growth, 
and differentiation. 
In the mouse, homozygous disruption of the 6th exon 
of the Evi1 gene lead to embryonic lethality, with 
widespread hypocellularity, reduced body size, small or 
absent limb buds, a pale yolk sac and placenta, 
abnormal development of the nervous system and the 
heart, and massive haemorrhaging. 
EVI1 is thought to exert its biological functions mainly 
by acting as a transcription factor. In addition, 
however, EVI1 has been reported to inhibit c-jun N-
terminal kinase, and to stimulate PI3K/AKT signalling. 
Homology 
EVI1 orthologs are present in many species. Evi1 
proteins from other mammals share more than 90% 
amino acid sequence identity with the human protein, 
and Xenopus Evi1 is 77% identical to its human 
counterpart. MDS1-EVI1 shares an overall homology 
with the C. elegans Egl 43 protein that includes the PR 
domain at the N-terminus and the two zinc-finger 
domains. An MDS1/EVI1 ortholog, hamlet, is also 
present in Drosophila. 
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Figure3. Normal and leukemia-associated EVI1 protein variants. 
 
Implicated in 
t(3;3)(q21;q26) or inv(3)(q21q26) 
Note: 3q21q26 syndrome. Chromosomal 
rearrangements located either 5' or 3' of the EVI1 gene 
can activate its transcription in haematopoietic cells.  
Usually, t(3;3)(q21;q26) breakpoints are located 5' of 
EVI1, and inv(3)(q21q26) breakpoints 3' of it. 
Nevertheless, in both cases aberrant expression of the 
EVI1 gene may be due to its juxtaposition to the 
enhancer of the constitutively expressed housekeeping 
gene ribophorin 1 at 3q21. 
Disease 
Acute Myelogenous Leukemia (AML), 
Myelodysplastic Syndrome (MDS), and Chronic 
Myelogenous Leukemia (CML). 
Prognosis 
Patients with EVI1 rearrangements have elevated 
platelet counts, marked hyperplasia with dysplasia of 
megakaryocytes, and a poor prognosis. 
Cytogenetics 
Rearrangements at 3q26 may occur as a sole anomaly, 
but are often associated with monosomy 7 or deletion 
of the long arm of chromosome 7, and, less frequently, 
deletion in chromosome 5. 
Oncogenesis 
Inappropriate expression of EVI1 in haematopoietic 
cells alters differentiation into granulocytes, 
erythrocytes and megakaryocytes. EVI1 promotes the 
proliferation of certain cell types, but inhibits the 
growth of others. It interferes with growth inhibiton by 
TGF-b and with apoptosis elicited by a variety of 
stimuli. In a murine bone marrow 
transduction/transplantation model, EVI1 caused a 
disease resembling human myelodysplastic syndrome. 













AML1-MDS1-EVI1 is a chimeric transcription factor 
that interferes with AML1 functions in a dominant 











Overexpression of a fusion protein between the amino 
terminus of TEL, which does not contain any 
functional domains, and the entire MDS1/EVI1 protein 
is driven by the TEL promoter. 










AML without 3q26 rearrangements. 
Note: EVI1 may also be overexpressed in AML, MDS, 
or CML in blast crisis in the absence of any 
cytogenetically detectable 3q26 rearrangements. 
Disease 






Note: Other chromosomal rearrangements that results 
in the inappropriate expression of EVI1 include 
t(2;3)(p13;q26), t(2;3)(q23;q26), t(3;7)(q27;q22), 
t(3;8)(q26;q24), t(3;13)(q26;q13-14), and 
t(3;17)(q26;q22). 
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